Trial Profile
A Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Tolerability of Multiple Dose Regimens of CHF 5074 (200, 400, 600 mg/Day for up to 12 Weeks) and to Explore the Effects on Potential Markers of Clinical Efficacy in Patients With Mild Cognitive Impairment
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Itanapraced (Primary)
- Indications Mild cognitive impairment
- Focus Adverse reactions
- Sponsors Chiesi; Chiesi Farmaceutici
- 08 Jan 2016 Primary endpoints has been revised according to ClinicalTrials.gov record.
- 26 Jul 2013 Interim data from the 90-week open-label extension study have been reported, according to a Chiesi Farmaceutici S.p.A. and CereSpir media release; 43 patients are expected to reach the 90-week endpoint at the end of 2013.
- 26 Jul 2013 Final results of the 14-week, double-blind study in 96 patients have been reported, according to a Chiesi Farmaceutici S.p.A. and CereSpir media release.